Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 25, 2010, Pages 2363-2368

  Stocker, Sophie L ^a   Franklin, Michael E ^b   Anderson, Jacqueline M ^c   Pillans, Peter I ^b   Williams, Kenneth M ^c   McLachlan, Andrew J ^a,d   Day, Richard O ^c   Taylor, Paul J ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ANZAC Research Institute   (Australia)

Author keywords

Gout; HPLC; Mass spectrometry; Oxypurinol; Urine

Indexed keywords

ACTIVE METABOLITES; AMMONIUM ACETATE; ANALYSIS TIME; ATLANTIS; CALIBRATION CURVES; CLINICAL TRIAL; FREEZE-THAW CYCLES; GOUT; HPLC; INTERNAL STANDARDS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MASS SPECTROMETRIC DETECTION; METHYLXANTHINE; MOBILE PHASE; OXYPURINOL; QUADRATIC REGRESSION; ROOM TEMPERATURE; SILICA COLUMN; TANDEM MASS SPECTROMETRY; URIC ACIDS; URINE; URINE SAMPLE; WEIGHTING FACTORS; XANTHINE OXIDASE;

AMMONIUM COMPOUNDS; CENTRIFUGATION; COLUMN CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; FORMIC ACID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ORGANIC ACIDS; QUALITY CONTROL; SILICA;

BODY FLUIDS;

ALLOPURINOL; OXIPURINOL;

ACCURACY; ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; GOUT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TEMPERATURE MEASUREMENT; URINE LEVEL;

ALLOPURINOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; GOUT; HUMANS; HYPERURICEMIA; OXYPURINOL; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; XANTHINES;

EID: 77955843370     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.07.017     Document Type: Article

References (24)

1. Terkeltaub R.A. N. Engl. J. Med. 2003, 249:1647.
2. Elion G.B., Kovensky A., et al. Biochem. Pharmacol. 1966, 15:863.
3. Day R.O., Graham G.G., et al. Clin. Pharmacokinet. 2007, 46:623.
4. Walter-Sack I., Grobner W., et al. Arzneimittelforschung 1979, 29:839.
5. Dalbeth N., Kumar S., et al. J. Rheumatol. 2006, 33:1646.
6. Vazquez-Mellado J., Morales E.M., et al. Ann. Rheum. Dis. 2001, 60:981.
7. Stamp L., Gow P., et al. Aust. N. Z. J. Med. 2000, 30:567.
8. Harrold L.R., Andrade S.E., et al. Arthritis Res. Ther. 2009, 11:R46.
9. Briesacher B.A., Andrade S.E., et al. Pharmacotherapy 2008, 28:437.
10. Riedel A.A., Nelson M., et al. J. Rheumatol. 2004, 31:1575.
11. Sarawate C.A., Brewer K.K., et al. Mayo Clin. Proc. 2006, 81:925.
12. Solomon D.H., Avorn J., et al. Ann. Rheum. Dis. 2008, 67:609.
13. Stocker S.L., Williams K.M., et al. Clin. Pharmacokinet. 2008, 47:111.
14. Breithaupt H., Goebel G. J. Chromatogr. 1981, 226:237.
15. de Vries J.X., Voss A., et al. Arzneimittelforschung 1993, 43:1072.
16. Failler J.M., Farinotti R., et al. Ther. Drug Monit. 1985, 7:324.
17. Buhrman D.L., Price P.I., et al. J. Am. Soc. Mass Spec. 1996, 7:1099.
18. Taylor P.J. Clin. Biochem. 2005, 38:328.
19. Palmisano F., Desimoni E., et al. J. Chromatogr. 1984, 306:205.
20. Voelter W., Zech K., et al. J. Chromatogr. 1980, 199:345.
21. Wessel T., Lanvers C., et al. J. Chromatogr. A 2000, 894:157.
22. Brown M., Bye A. J. Chromatogr. 1977, 143:195.
23. Moriwaki Y., Yamamoto T., et al. Metabolism 2002, 51:893.
24. FDA Guidance for Industry: Bioanalytical Method Validation 2001, US Department of Health and Human Services, FDA Center for Drug Evaluation and Research (CDER), Rockville, Maryland.